Tesamorelin Dosage: How It's Used

If you search “tesamorelin dosage,” you’re asking a reasonable question about a real, FDA-approved drug — and that’s what makes the answer different from most of the compounds covered on this site. Tesamorelin actually has an official label dose, validated in clinical trials and printed in prescribing information. It is not a forum guess.

But “there is a real dose” is not the same as “here is a number you can use.” Tesamorelin’s dose is genuine, fixed, and tightly bound to one approved use. The moment that number is lifted off the label and applied to a different goal, a different person, and an unregulated vial, almost everything that made it a safe, sensible dose falls away. This page explains how tesamorelin dosing actually works, why it doesn’t titrate, and why the version of “tesamorelin dosage” circulating online is misleading even though it borrows a real figure.

How tesamorelin dosing is actually determined

Tesamorelin is a growth-hormone-releasing factor (GHRF) analog. In the US it is approved and sold as Egrifta, indicated for the reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy. That is its one approved indication — not weight loss, not anti-aging, not general body recomposition. The label is explicit that it is not indicated for weight management.

For that approved use, the dose is set the way any prescription drug’s dose is set: a licensed prescriber evaluates the patient, confirms the diagnosis, screens for contraindications (active malignancy and elevated IGF-1 are specific concerns for a GH-axis drug), and then the patient receives the approved label dose. It isn’t reverse-engineered from a website, and it isn’t a number the patient chooses. The dose is one part of a clinical relationship that also includes monitoring and follow-up.

Note: Throughout this page, dosing is described in terms of its shape — once daily, fixed, under the skin — rather than as a copyable recipe. The approved label specifies the exact amount for prescribers and the patients they treat; the point here is how dosing is decided, not a do-it-yourself protocol.

The thing that makes tesamorelin different: the dose doesn’t titrate

This is the single most important and most overlooked fact about tesamorelin dosing, and it sets it apart from almost every other injectable people research.

The GLP-1 drugs that dominate weight-loss conversations — semaglutide, tirzepatide — are titrated. You start at a deliberately low, sub-therapeutic dose and step it up over weeks to let the body tolerate it. That “start low, go slow” ladder is so central to those drugs that people assume every injectable works the same way, and they go looking for a tesamorelin “ramp.”

There isn’t one. The approved tesamorelin label uses a single fixed dose, injected once a day, with no escalation schedule. You don’t begin low and climb. There is no maintenance dose that’s higher than the starting dose, because there is no starting-versus-maintenance distinction at all. One level, every day.

That matters for two reasons. First, it means any online “tesamorelin titration protocol” — start here, increase by this much each week, work up to this — is fabricated. It’s importing a structure from a different class of drug onto one that doesn’t use it. Second, it removes the usual rationale people give for self-experimenting with dose (“I’ll just titrate carefully”). There’s nothing to titrate. More isn’t the lever, and “ramping up” isn’t a thing this drug does.

Why the off-label number doesn’t transfer

Here’s the trap specific to tesamorelin. Because there is a real, official label dose, the internet has something concrete to copy — and it copies it onto situations the dose was never validated for.

The approved dose belongs to HIV-associated lipodystrophy. The overwhelming majority of people searching “tesamorelin dosage” are not in that population. They’re healthy adults interested in visceral-fat reduction, body composition, or anti-aging. For those uses, tesamorelin is off-label, and the evidence base is dramatically thinner — a small number of studies, not the pivotal trial program behind the approved indication.

But the dose people use is the lipodystrophy number anyway, stripped of the indication, the patient profile, and the monitoring it was studied with. There is no separately validated “anti-aging dose” or “recomp dose” to reach for, so the label figure gets transplanted whole. That’s the quiet sleight of hand: a number that is genuinely evidence-based for one condition is presented as the right dose for a completely different goal, where its evidence is weak to nonexistent. The number looks legitimate precisely because, in its original context, it is.

Reconstitution: where the real risk lives

Tesamorelin isn’t a ready-to-inject liquid. It’s supplied as a freeze-dried powder that has to be reconstituted — mixed with a specific diluent — before it’s injected under the skin. The approved products standardize this completely: each comes with the exact diluent, exact instructions, and a defined number of doses per vial. (The newer formulation is mixed once a week and injected daily; the older one is mixed fresh each day. Same molecule, different handling.) The manufacturing, sterility, concentration, and identity are all controlled before the vial ever reaches a patient.

Now consider the gray-market version. Someone buys a “research” vial of tesamorelin powder of unknown actual content, reconstitutes it themselves, draws up a dose based on a number from a website, and injects it. Every protective layer the approved product builds in — verified identity, verified concentration, controlled sterility, defined dosing — has been handed back to the user, who has none of the tools to recreate it. This is the core hazard the addendum to good practice keeps returning to: the right dose of the wrong or unverified product is still wrong. A vial that contains more, less, or something other than what the label claims makes the arithmetic meaningless. You can match the official number perfectly and still be injecting something that isn’t what you think it is.

Explaining what reconstitution is is reasonable. Treating a public website as a place to learn how to mix and measure an unregulated injectable is not, and this page won’t do it.

Monitoring and the red flags

For the approved use, dosing is only half of the picture; the other half is oversight. A legitimate provider tracks IGF-1 (because the drug stimulates growth hormone), watches for fluid retention and glucose changes, screens against active cancer, and reassesses whether the drug is doing what it’s supposed to. The dose without that scaffolding is not “the same treatment minus some paperwork” — it’s a different, riskier thing.

So the warning sign isn’t a particular number. It’s the absence of the process around the number. A vendor that will sell you tesamorelin with no evaluation, a “dosing chart” sitting next to a buy button, a protocol that promises a body-recomposition outcome from a fixed daily injection with no monitoring at all — these are the tells. “No eval, just this schedule” is the red flag, regardless of whether the schedule happens to match the label.

Where tesamorelin sits legally

Tesamorelin is genuinely FDA-approved, which puts it in a different position from most of the research peptides discussed on this site. It is not caught up in the 2026 Category 1/Category 2 reclassification story — its status rests on the Egrifta approval, not on pending rulemaking. For the approved HIV-lipodystrophy indication, it’s prescribed and dispensed through normal pharmacy channels. Off-label prescribing is legal at a provider’s discretion but cash-pay and built on weaker evidence, and gray-market “research” vials are unregulated products outside the legitimate route entirely. The dosing question, in other words, can’t be separated from which of those routes you’re actually on. For how that access works, see how to get tesamorelin in the US and the tesamorelin prescription process; for the wider legal framework, see are peptides legal in the US?

The bottom line

Tesamorelin is the unusual case where a real, validated dose exists — and that’s exactly why the internet version of “tesamorelin dosage” is so persuasive and so misleading. The approved dose is a single fixed once-daily injection, never titrated, set by a prescriber for one specific medical condition, dispensed as a quality-controlled product, and watched over time. Strip away the indication, the prescriber, the verified product, and the monitoring, and you’re left with a number floating free of everything that made it meaningful. The figure survives the copy-paste; the safety doesn’t.

If your interest is the approved use, that’s a conversation with a qualified provider, not a website. If your interest is off-label fat loss or anti-aging, the honest answer is that there’s no validated dose for that — and an FDA-approved GLP-1 medication, with a real prescriber-set regimen and a lawful channel, is the route with the evidence and the oversight behind it.